Literature DB >> 22241710

Autonomic dysfunction in childhood Guillain-Barré syndrome.

Francis J Dimario1, Carrie Edwards.   

Abstract

This investigation correlated incidence and degree of autonomic dysfunction with the degree of motor impairment in children hospitalized with Guillain-Barré syndrome. Motor weakness varies, as does the effect on autonomic function including heart rate, vasomotor stability, sweating, continence, and blood pressure. After Institutional Review Board approval, hospitalized patients with Guillain-Barré syndrome <19 years were included for retrospective chart review. There were 26 patients (12 boys), with a mean age of 11.3 years (range, 6-17 years). The average hospital stay was 10.6 days. Twenty-four (92%) recovered by 2 to 6 months without functional disability. Bradycardia and sweating disturbances were not observed. Hypertension occurred in 18 of 26 (69%) and tachycardia in 20 of 26 (77%) patients. The proportion of children with hypertension and/or tachycardia increased, as did the motor disability grade (P < .043 and P < .018, respectively). Hypertension occurred 9 to 15 days from symptom onset and within 24 to 48 hours of maximum motor disability in 89%. Multiple autonomic disturbances compound the course of childhood Guillain-Barré syndrome.

Entities:  

Mesh:

Year:  2012        PMID: 22241710     DOI: 10.1177/0883073811420872

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  11 in total

1.  Bladder dysfunction and hypertension in children with Guillain-Barre syndrome.

Authors:  Louise Watson; Majid Aziz; Grace Vassallo; Nicholas D Plant; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2014-03-22       Impact factor: 3.714

2.  Pediatric guillain-barré syndrome and autonomic dysfunction.

Authors:  Ertugrul Kurtoglu; Sevket Balta; Yasin Karakus; Erdogan Yasar
Journal:  J Cardiovasc Thorac Res       Date:  2013-12-05

3.  Guillain-Barré syndrome in children: subtypes and outcome.

Authors:  Zeynep Selen Karalok; Birce Dilge Taskin; Zeliha Brohi Yanginlar; Esra Gurkas; Alev Guven; Aydan Degerliyurt; Ece Unlu; Gulsen Kose
Journal:  Childs Nerv Syst       Date:  2018-06-14       Impact factor: 1.475

4.  Assessment of autonomic dysfunction in childhood guillain-barré syndrome.

Authors:  Mahmood Samadi; Babak Kazemi; Sona Golzari Oskoui; Mohammad Barzegar
Journal:  J Cardiovasc Thorac Res       Date:  2013-10-05

5.  A Case of Visceral Autonomic Neuropathy Complicated by Guillain-Barre Syndrome Accompanied with Cyclic Vomiting Syndrome-like Disorder in a Child.

Authors:  Suk Jin Hong; Byung-Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2015-06-29

6.  Yet Another Atypical Presentation of Anti-GQ1b Antibody Syndrome.

Authors:  Raed Alroughani; Anil Thussu; Raouf T Guindi
Journal:  Neurol Int       Date:  2015-09-24

7.  Acute idiopathic polyradiculoneuritis with secondary arterial hypertension in a 5-year-old male Siberian Husky.

Authors:  Mihai Musteata; Raluca Ștefănescu; Andrei Radu Baisan; Diana Mocanu; Sorin Aurelian Pașca; Luminița Diana Hrițcu; Mădălina Henea; Gheorghe Solcan
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

8.  Association Between the Rate of Treatment Response and Short-Term Outcomes in Childhood Guillain-Barré Syndrome.

Authors:  Mei Jin; Libo Zhao; Jing Liu; Weijin Geng; Ziwei Zhao; Chunzhen Li; Jingru Xue; Suzhen Sun
Journal:  Front Neurol       Date:  2021-11-05       Impact factor: 4.003

9.  Distinct Clinical Characteristics of Pediatric Guillain-Barré Syndrome: A Comparative Study between Children and Adults in Northeast China.

Authors:  Xiujuan Wu; Donghui Shen; Ting Li; Bing Zhang; Chunrong Li; Mei Mao; Jixue Zhao; Kangding Liu; Hong-Liang Zhang
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

10.  Initial Response and Outcome of Critically Ill Children With Guillain Barre' Syndrome.

Authors:  Hafez M Bazaraa; Hanaa I Rady; Shereen A Mohamed; Walaa A Rabie; Noha H ElAnwar
Journal:  Front Pediatr       Date:  2019-09-18       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.